Top Companies in the Liver Disease Treatment Market

The liver disease treatment market was valued at USD 20.14 billion in 2023, driven by the increasing prevalence of liver disease across the 8 major markets. The market is expected to grow at a CAGR of 10.4% during the forecast period of 2024-2032, with the values likely to reach USD 48.88 billion by 2032.

Liver disease includes any medical condition that damages the liver and impacts its functioning. The treatment for liver disease depends on the specific type of liver disease, its severity, and the causing agent. For hepatitis B  and C treatments, antiviral drugs are taken to slow the progression of liver damage. In nonalcoholic steatohepatitis (NASH), medications that improve insulin sensitivity or lower lipid levels are generally prescribed. The market is witnessing increased research activities aimed at exploring ways to repair or replace damaged liver tissue which is likely to fuel the market growth.

Recent data indicates that liver or hepatic disease affects over 100 million individuals in the United States. It is estimated that around 4.5 million adults, comprising 1.8% of the population, have been diagnosed with liver disease. However, nearly 80 to 100 million U.S. adults are reported to have undiagnosed fatty liver disease in varying stages. The increasing burden of liver diseases, driven by factors such as alcohol consumption, obesity, unhealthy lifestyles, and viral infections, is expected to propel the demand for effective treatment options.

The increasing use of non-invasive diagnostic tools, such as elastography and imaging technologies like MRI and CT scans, is a major market trend. These technologies facilitate early detection and monitoring of liver conditions without the need for invasive biopsies. Further, the interest towards combination therapies is rising in the market, especially for complex liver conditions such as hepatitis C and liver cancer.

The market benefits from the heightened awareness of liver diseases and the importance of early diagnosis. This is prompting more individuals to seek medical attention, which is also contributing to the increase in market demand. Moreover, government initiatives directed at tackling liver diseases, such as hepatitis vaccination programs and public health campaigns, are anticipated to support the market expansion for liver disease treatment in the coming years.

Top Companies Leading the Liver Disease Treatment Market in 2024

1.    Abbott Laboratories

Abbott Laboratories, an American multinational healthcare company, has a prominent presence in the market. The company is focused on expanding its diagnostic capabilities for detecting liver diseases through the development of molecular diagnostics and advanced immunoassays. Abbott is also heavily investing in research and development to improve early detection methods for liver conditions like hepatitis and liver cancer. Besides its focus on liver disease diagnostics, Abbott's key offerings include antiviral medications for the treatment of hepatitis. One of its liver disease drugs is SILLIVER®(Silymarin)  which is indicated as an adjunctive therapy for liver disease of varying etiologies such as chronic persistent and chronic aggressive hepatitis and fatty liver.

2.    Astellas Pharma Inc.

Japanese multinational pharmaceutical company Astellas Pharma Inc. is one of the leading players in the market, known for its advanced therapies for chronic liver conditions and liver cancer. The company is expanding the portfolio of its immunosuppressive drugs which are needed for liver transplant patients. For instance, PROGRAF®(tacrolimus)  is a prescription medicine developed by Astellas that is used in combination with other drugs to prevent organ rejection in individuals with a liver transplant. Astellas is also engaged in enhancing the efficacy and safety profiles of its drugs by investing in research activities and thus significantly contributing to the market growth.

3.    Bristol-Myers Squibb Company

Bristol Myers Squibb, one of the world's largest pharmaceutical companies, is actively engaged in the development of innovative therapies that address unmet medical needs in liver disease treatment. The company is advancing its research towards the development of next-generation antiviral therapies for hepatitis B and C. Baraclude (Entecavir) is one of its antiviral medications used for the treatment of chronic hepatitis B virus infection in adult patients with persistent elevations in serum aminotransferases (ALT or AST) or evidence of active viral replication. Further, in March 2024, Bristol Myers Squibb reported positive phase 3 results for its immune-oncology combination of Opdivo (nivolumab) and Yervoy (ipilimumab) drugs for the treatment of advanced hepatocellular carcinoma (HCC) in patients with no prior systemic therapy.

4.    GlaxoSmithKline PLC

GSK plc is a pharmaceutical industry company with its global headquarters located in London. The company plays a significant role in the market growth by developing vaccines, antiviral medications, and other therapies for the prevention and treatment of various liver diseases. GSK is also involved in research activities that aim to find new treatments for liver-related conditions. The company is known for its hepatitis B vaccine Engerix-B which provides protection against hepatitis B infection. Engerix-B is widely used in vaccination programs around the world. Further, in February 2024, the United States Food and Drug Administration (FDA) granted Fast Track designation for GSK's investigational antisense oligonucleotide (ASO) bepirovirsen to treat chronic hepatitis B (CHB).

5.    F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche, commonly known as Roche, boasts a strong presence in the liver disease treatment market. It is involved in the development of targeted therapies for liver diseases, including liver cancer. Roche's offerings include antiviral drugs, such as Pegasys (peginterferon α) for the treatment of hepatitis B and C. Moreover, in January 2023, Roche announced that in the Phase III IMbrave050 study, its cancer immunotherapy combination therapy Tecentriq (atezolizumab) and Avastin (bevacizumab) achieved the primary efficacy endpoint in early-stage hepatocellular carcinoma.